Literature DB >> 12237252

Metformin enhances insulin signalling in insulin-dependent and-independent pathways in insulin resistant muscle cells.

Naresh Kumar1, Chinmoy S Dey.   

Abstract

1 Metformin lowers blood glucose levels in type 2 diabetic patients. To evaluate the insulin sensitizing action of metformin on skeletal muscle cells, we have used C2C12 skeletal muscle cells differentiated in chronic presence or absence of insulin. 2 Metformin was added during the last 24 h of differentiation of the C2C12 myotubes. Insulin-stimulated tyrosine phosphorylation of insulin receptor (IR) and insulin receptor substrate-1 (IRS-1) was determined. 3 Chronic insulin treatment resulted in 60 and 40% reduction in insulin-stimulated tyrosine phosphorylation of IR and IRS-1, respectively. Treatment with metformin was able to increase the tyrosine phosphorylation of IR and IRS-1 by 100 and 90% respectively. 4 Chronic insulin treatment drastically reduced (45%) insulin-stimulated phosphatidyl inositol 3-kinase (PI 3-kinase) activity. Metformin treatment restored PI 3-kinase activity in insulin-resistant myotubes. 5 Insulin-stimulated glucose uptake was impaired in chronically insulin-treated myotubes. Metformin increased basal glucose uptake to significant levels (P<0.05), but metformin did not increase insulin-stimulated glucose transport. 6 All the three mitogen-activated protein kinases (MAPK) were activated by insulin in sensitive myotubes. The activation of p38 MAPK was impaired in resistant myotubes, while ERK and JNK were unaffected. Treatment with metformin enhanced the basal activation levels of p38 in both sensitive and resistant myotubes, but insulin did not further stimulate p38 activation in metformin treated cells. 7 Treatment of cells with p38 inhibitor, SB203580, blocked insulin- and metformin-stimulated glucose uptake as well as p38 activation. 8 Since the effect of metformin on glucose uptake corresponded to p38 MAPK activation, this suggests the potential role p38 in glucose uptake. 9 These data demonstrate the direct insulin sensitizing action of metformin on skeletal muscle cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237252      PMCID: PMC1573500          DOI: 10.1038/sj.bjp.0704878

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  Chronic insulin effects on insulin signalling and GLUT4 endocytosis are reversed by metformin.

Authors:  P R Pryor; S C Liu; A E Clark; J Yang; G D Holman; D Tosh
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

2.  Activation of p38 mitogen-activated protein kinase alpha and beta by insulin and contraction in rat skeletal muscle: potential role in the stimulation of glucose transport.

Authors:  R Somwar; M Perreault; S Kapur; C Taha; G Sweeney; T Ramlal; D Y Kim; J Keen; C H Côte; A Klip; A Marette
Journal:  Diabetes       Date:  2000-11       Impact factor: 9.461

3.  Differentiation of myoblasts in serum-free media: effects of modified media are cell line-specific.

Authors:  M A Lawson; P P Purslow
Journal:  Cells Tissues Organs       Date:  2000       Impact factor: 2.481

4.  Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways.

Authors:  L Rui; V Aguirre; J K Kim; G I Shulman; A Lee; A Corbould; A Dunaif; M F White
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 5.  The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms.

Authors:  N F Wiernsperger; C J Bailey
Journal:  Drugs       Date:  1999       Impact factor: 9.546

6.  Metformin, but not exercise training, increases insulin responsiveness in skeletal muscle of Sprague-Dawley rats.

Authors:  S E Borst; H G Snellen
Journal:  Life Sci       Date:  2001-08-17       Impact factor: 5.037

Review 7.  Insulin-sensitive phospholipid signaling systems and glucose transport. Update II.

Authors:  R V Farese
Journal:  Exp Biol Med (Maywood)       Date:  2001-04

8.  Insulin produces myogenesis in C2C12 myoblasts by induction of NF-kappaB and downregulation of AP-1 activities.

Authors:  R Conejo; A M Valverde; M Benito; M Lorenzo
Journal:  J Cell Physiol       Date:  2001-01       Impact factor: 6.384

9.  Tumor necrosis factor alpha-mediated insulin resistance, but not dedifferentiation, is abrogated by MEK1/2 inhibitors in 3T3-L1 adipocytes.

Authors:  J A Engelman; A H Berg; R Y Lewis; M P Lisanti; P E Scherer
Journal:  Mol Endocrinol       Date:  2000-10

10.  The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307).

Authors:  V Aguirre; T Uchida; L Yenush; R Davis; M F White
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

View more
  29 in total

1.  The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro.

Authors:  N K Verma; C S Dey
Journal:  Diabetologia       Date:  2006-05-03       Impact factor: 10.122

2.  Altered PPARgamma expression inhibits myogenic differentiation in C2C12 skeletal muscle cells.

Authors:  Jaskirat Singh; Navin Kumar Verma; Sejal M Kansagra; Bhusan N Kate; Chinmoy Sankar Dey
Journal:  Mol Cell Biochem       Date:  2006-07-13       Impact factor: 3.396

3.  Hydrogen sulfide treatment promotes glucose uptake by increasing insulin receptor sensitivity and ameliorates kidney lesions in type 2 diabetes.

Authors:  Rong Xue; Dan-Dan Hao; Ji-Ping Sun; Wen-Wen Li; Man-Man Zhao; Xing-Hui Li; Ying Chen; Jian-Hua Zhu; Ying-Jiong Ding; Jun Liu; Yi-Chun Zhu
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

4.  PPAR-gamma expression modulates insulin sensitivity in C2C12 skeletal muscle cells.

Authors:  Navin K Verma; Jaskirat Singh; Chinmoy S Dey
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

5.  Focal adhesion kinase regulates insulin resistance in skeletal muscle.

Authors:  B Bisht; H L Goel; C S Dey
Journal:  Diabetologia       Date:  2007-02-28       Impact factor: 10.122

6.  Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling.

Authors:  Roberta Malaguarnera; Antonella Sacco; Alaide Morcavallo; Sebastiano Squatrito; Antimo Migliaccio; Andrea Morrione; Marcello Maggiolini; Antonino Belfiore
Journal:  Endocrinology       Date:  2014-01-17       Impact factor: 4.736

Review 7.  Molecular mechanisms involved in NAFLD progression.

Authors:  Mariano Malaguarnera; Michelino Di Rosa; Ferdinando Nicoletti; Lucia Malaguarnera
Journal:  J Mol Med (Berl)       Date:  2009-04-08       Impact factor: 4.599

8.  NYGGF4 (PID1) effects on insulin resistance are reversed by metformin in 3T3-L1 adipocytes.

Authors:  Jie Qiu; Yu-Mei Wang; Chun-Mei Shi; Hong-Ni Yue; Zhen-Ying Qin; Guan-Zhong Zhu; Xin-Guo Cao; Chen-Bo Ji; Yan Cui; Xi-Rong Guo
Journal:  J Bioenerg Biomembr       Date:  2012-09-12       Impact factor: 2.945

9.  Concentrations of signal transduction proteins exercise and insulin responses in rat extensor digitorum longus and soleus muscles.

Authors:  Philip J Atherton; James M Higginson; Jaipaul Singh; Henning Wackerhage
Journal:  Mol Cell Biochem       Date:  2004-06       Impact factor: 3.396

10.  Metformin regulates glucose transporter 4 (GLUT4) translocation through AMP-activated protein kinase (AMPK)-mediated Cbl/CAP signaling in 3T3-L1 preadipocyte cells.

Authors:  Jung Ok Lee; Soo Kyung Lee; Ji Hae Kim; Nami Kim; Ga Young You; Ji Wook Moon; Su Jin Kim; Sun Hwa Park; Hyeon Soo Kim
Journal:  J Biol Chem       Date:  2012-11-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.